{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:05:38Z","timestamp":1784009138969,"version":"3.55.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant immunotherapy\/targeted therapy combined with chemotherapy shows encouraging activity for oropharyngeal squamous cell carcinoma (OPSCC). However, evidence specific to tonsillar squamous cell carcinoma (TSCC) remains limited, particularly regarding the systematic relationships among radiological response, pathologic response, margin control, and voice and swallowing functional outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-arm, single-center study included patients with pathologically confirmed TSCC diagnosed between January 2024 and June 2025. Patients received triplet neoadjuvant therapy consisting of nimotuzumab, toripalimab, nab-paclitaxel, and carboplatin every 3 weeks for 2 cycles, followed by transoral radical tonsillectomy combined with radical cervical lymph node dissection. Radiologic response was assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and volumetric magnetic resonance imaging (MRI). Pathologic response, margin status, perioperative safety, adjuvant treatment, and functional outcomes were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty patients achieved clinicopathologic downstaging after surgery. The primary-site pCR rate was 65.0%, nodal pCR was 60.0%, and overall ypT0N0 pCR was 45.0%. The objective radiological response (ORR) rate of the primary lesion was 100%, and 9 patients (45%) achieved a complete radiological response. Mean primary-tumor and dominant-node volume reductions were 76.18% and 72.59%, respectively. Both pre- and postneoadjuvant margins were negative in all patients, yielding R0 resection in all cases. Functional scores improved after neoadjuvant therapy, worsened transiently during radiotherapy, and generally recovered during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nimotuzumab plus toripalimab and chemotherapy produced high radiological and pathological response rates with reliable margin control in patients with locally advanced TSCC. Postneoadjuvant boundary assessment with intraoperative pathologic verification may support individualized resection planning, but routine resection of the primary lesion and cervical lymph node dissection remain necessary. Longer follow-up and prospective validation are required to confirm these results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:related-object>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/study\/<\/jats:ext-link>\n                      , identifier NCT07353723.\n                    <\/jats:related-object>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1890647","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:37:26Z","timestamp":1784007446000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["An exploratory study of nimotuzumab combined with toripalimab and chemotherapy for locally advanced tonsillar cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Jingxuan","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"School of Medicine, Northwest University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leping","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanyin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjie","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cden.2017.08.008","article-title":"Human papillomavirus and oropharyngeal cancer","volume":"62","author":"Tanaka","year":"2018","journal-title":"Dent Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000441902","article-title":"Studies of tonsils in basic and clinical perspectives: From the past to the future","volume":"77","author":"Yamashita","year":"2016","journal-title":"Adv Otorhinolaryngol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.wjorl.2021.04.003","article-title":"Anatomy and physiology of the palatine tonsils, adenoids, and lingual tonsils","volume":"7","author":"Arambula","year":"2021","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21758","article-title":"Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer","volume":"73","author":"Kang","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00603-7","article-title":"HPV-associated oropharyngeal cancer: Epidemiology, molecular biology and clinical management","volume":"19","author":"Lechner","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.38.4099","article-title":"Tobacco smoking and increased risk of death and progression for patients with P16-positive and P16-negative oropharyngeal cancer","volume":"30","author":"Gillison","year":"2012","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.6004\/jnccn.2025.0007","article-title":"NCCN Guidelines\u00ae insights: Head and neck cancers, version 2.2025","volume":"23","author":"Colevas","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001306","article-title":"Surgical margins in head and neck squamous cell carcinoma: A narrative review","volume":"110","author":"Chen","year":"2024","journal-title":"Int J Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hed.10106","article-title":"The addition of mood and anxiety domains to the University of Washington Quality of Life Scale","volume":"24","author":"Rogers","year":"2002","journal-title":"Head Neck"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.127.7.870","article-title":"The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: The M. D. Anderson Dysphagia Inventory","volume":"127","author":"Chen","year":"2001","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/000348940811701210","article-title":"Validity and reliability of the eating assessment tool (EAT-10)","volume":"117","author":"Belafsky","year":"2008","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-200409000-00009","article-title":"Development and validation of the voice handicap index-10","volume":"114","author":"Rosen","year":"2004","journal-title":"Laryngoscope"},{"key":"B15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1044\/1058-0360.0603.66","article-title":"The voice handicap index (VHI)","volume":"6","author":"Jacobson","year":"1997","journal-title":"Am J Speech Lang Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2016.06.002","article-title":"Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer","volume":"59","author":"Licitra","year":"2016","journal-title":"Oral Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/s41467-024-46444-z","article-title":"Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: A pilot phase II trial","volume":"15","author":"Wu","year":"2024","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1530","article-title":"Neoadjuvant nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+ oropharyngeal cancer: OPTIMA II phase 2 open-label nonrandomized controlled trial","volume":"10","author":"Rosenberg","year":"2024","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.68.3300","article-title":"E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group","volume":"35","author":"Marur","year":"2017","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206039","article-title":"A comprehensive systematic review on functional results, speech and swallowing outcomes after trans-oral robotic surgery for oropharyngeal squamous cell cancer","volume":"13","author":"Guarino","year":"2024","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable P16+ locally advanced oropharynx cancer: An ECOG-ACRIN Cancer Research Group trial (E3311)","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/lary.23900","article-title":"Margin mapping in transoral surgery for head and neck cancer","volume":"123","author":"Hinni","year":"2013","journal-title":"Laryngoscope"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2015.07.005","article-title":"Narrow band imaging in the intra-operative definition of resection margins in oral cavity and oropharyngeal cancer","volume":"51","author":"Tirelli","year":"2015","journal-title":"Oral Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.04.8306","article-title":"Epidermal growth factor receptor biology in head and neck cancer","volume":"24","author":"Kalyankrishna","year":"2006","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32179","article-title":"A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer","volume":"125","author":"Patil","year":"2019","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00136-4","article-title":"Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: An open-label, multi-arm, non-randomised, multicentre, phase 2 trial","volume":"22","author":"Sacco","year":"2021","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-3849","article-title":"Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Chung","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/jco.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/cdd.2013.75","article-title":"Molecular mechanisms of ATP secretion during immunogenic cell death","volume":"21","author":"Martins","year":"2014","journal-title":"Cell Death Diff"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1152934","article-title":"Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review","volume":"14","author":"Zhai","year":"2023","journal-title":"Front Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-12-2426","article-title":"Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients","volume":"19","author":"Srivastava","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ctrv.2017.11.008","article-title":"Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation","volume":"63","author":"Ferris","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2025.4573","article-title":"Pathologic response and survival after neoadjuvant immunotherapy for resectable mucosal HNSCC: A systematic review and meta-analysis","volume":"152","author":"Mastrolonardo","year":"2026","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s1470-2045(25)00649-7","article-title":"Evaluation of progression-free status at 24 months as a surrogate endpoint for overall survival in patients with human papillomavirus-positive oropharyngeal cancer: A retrospective cohort study","volume":"27","author":"Cao","year":"2026","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1890647\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:37:27Z","timestamp":1784007447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1890647\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2026.1890647"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1890647","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"article-number":"1890647"}}